PH23658A - Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor - Google Patents

Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor

Info

Publication number: PH23658A
Authority: PH; Philippines
Prior art keywords: interleukin; ornithine decarboxylase; improved method; decarboxylase inhibitor; treating tumors
Prior art date: 1986-05-06

Application number

PH35211A

Other languages

English (en)

Inventor

Terry L Bowlin

Sai Prasad Sunkara

Original Assignee

Merrell Dow Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-05-06

Filing date

1987-05-04

Publication date

1989-09-27

1987-05-04 Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma

1989-09-27 Publication of PH23658A publication Critical patent/PH23658A/en

Links

239000002818 ornithine decarboxylase inhibitor Substances 0.000 title abstract 3
102000000588 Interleukin-2 Human genes 0.000 title abstract 2
108010002350 Interleukin-2 Proteins 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title abstract 2
229940122060 Ornithine decarboxylase inhibitor Drugs 0.000 title abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
230000004073 interleukin-2 production Effects 0.000 abstract 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

PH35211A 1986-05-06 1987-05-04 Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor PH23658A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US86016686A	1986-05-06	1986-05-06

Publications (1)

Publication Number	Publication Date
PH23658A true PH23658A (en)	1989-09-27

Family

ID=25332641

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH35211A PH23658A (en)	1986-05-06	1987-05-04	Improved method of treating tumors with autologous lymphokine activated killer,interleukin-2 and an ornithine decarboxylase inhibitor

Country Status (6)

Country	Link
EP (1)	EP0248217B1 (de)
JP (1)	JPS62263127A (de)
AT (1)	ATE91899T1 (de)
CA (1)	CA1318586C (de)
DE (1)	DE3786705D1 (de)
PH (1)	PH23658A (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4690915A (en) *	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
ZA903804B (en) *	1989-05-23	1991-03-27	Merrell Dow Pharma	A method of potentiating cell-mediated immunity utilizing polyamine derivatives
FR2706254B1 (fr) *	1993-06-17	1995-08-25	Univ Rennes	Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines.
FR2706255B1 (fr) *	1993-06-17	1995-10-27	Univ Rennes	Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
EP3478278B1 (de)	2016-07-01	2024-06-12	Agency for Science, Technology and Research	Verfahren zur bestimmung von akuten oder nicht heilenden wunden

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4499072A (en) *	1982-11-29	1985-02-12	Merrell Dow Pharmaceuticals Inc.	Process for treating diseases with ODC inhibitors

1987
- 1987-05-01 JP JP62106477A patent/JPS62263127A/ja active Pending
- 1987-05-04 EP EP87106439A patent/EP0248217B1/de not_active Expired - Lifetime
- 1987-05-04 AT AT87106439T patent/ATE91899T1/de active
- 1987-05-04 PH PH35211A patent/PH23658A/en unknown
- 1987-05-04 DE DE8787106439T patent/DE3786705D1/de not_active Expired - Lifetime
- 1987-05-05 CA CA000536385A patent/CA1318586C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0248217B1 (de)	1993-07-28
EP0248217A2 (de)	1987-12-09
CA1318586C (en)	1993-06-01
EP0248217A3 (en)	1989-11-08
ATE91899T1 (de)	1993-08-15
DE3786705D1 (de)	1993-09-02
JPS62263127A (ja)	1987-11-16

Similar Documents

Publication	Publication Date	Title
CA2291065A1 (en)	1998-11-26	Raf kinase inhibitors
BR9607894A (pt)	1999-06-01	Processo para tratar tumores
ATE275948T1 (de)	2004-10-15	Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung
DE3687099D1 (de)	1992-12-17	Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
KR880701736A (ko)	1988-11-04	Il-6의 제조방법 및 용도
ATE281840T1 (de)	2004-11-15	Behandlung von diarrhoe
ES2151607T3 (es)	2001-01-01	Factor 12 de crecimiento y de diferenciacion.
ATE232394T1 (de)	2003-02-15	Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE68921979D1 (de)	1995-05-04	Antikörper für die antilymphozyten-antikörpertherapie.
DE59407809D1 (de)	1999-03-25	Tumorizide t-lymphozyten
MY131053A (en)	2007-07-31	2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
EP0248217A3 (en)	1989-11-08	Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
ATE352306T1 (de)	2007-02-15	Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
EA199900091A1 (ru)	1999-08-26	Терапевтическое применение t-bam(cd40l)-технологии для лечения заболеваний с участием клеток гладкой мускулатуры
ES2039578T3 (es)	1993-10-01	Procedimiento para producir mercapto-acilaminoacidos antihipertensivos.
DE3879575D1 (de)	1993-04-29	Alpha-carotin zur wachstumshemmung von krebszellen.
DE3861494D1 (de)	1991-02-14	Pharmazeutische zusammensetzung zur behandlung von tumoren.
EP0257962A3 (de)	1989-05-24	Verfahren zur Behandlung von Umkreisblut für die Verbesserung der lymphokinaktivierten Töterzell-Immuntherapie
ATE128964T1 (de)	1995-10-15	Anwendung von beta-alethin in zellkultur und therapie.
DE3485282D1 (de)	1992-01-02	Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
GEP20012377B (en)	2001-03-25	Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
GR3018004T3 (en)	1996-02-29	Process to prepare metastasis-inhibitory factor.
AU1502388A (en)	1988-10-27	Use of odc inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma
ES8702863A1 (es)	1987-01-16	Procedimiento para la obtencion de un complejo salino de acido aspartico,magnesio y acido bromhidrico
DE59008759D1 (de)	1995-04-27	Verwendung von interleukin-2 zur behandlung der endotoxinämie.